von Willebrand Factor Plasma Levels May Affect Future Venous Thromboembolism Risk
A population-based analysis suggested that plasma levels of von Willebrand factor may be a potential biomarker for the future risk of incident venous thromboembolism.
A population-based analysis suggested that plasma levels of von Willebrand factor may be a potential biomarker for the future risk of incident venous thromboembolism.
A novel diagnostic algorithm was able to safely rule out DVT in patients visiting an emergency department, thereby reducing the need for ultrasound imaging.
In minor procedures, coagulation differences may not be clinically significant to determine bleeding or thrombotic periprocedure complication risks.
Patients with thrombophilia demonstrate an elevated risk for venous thromboembolism after undergoing orthopedic surgery.
New research has not found RBC transfusion to be an independent risk factor for venous or arterial thrombosis in hospitalized patients.
The American Society of Hematology released evidence-based guidelines for the treatment of DVT and PE in patients without cancer.
A prospective, single-center study aimed to determine the prevalence of DVT after TKA among patients with hemophilia A and found that contrast-enhanced CT led to better detection compared with ultrasound.
The British Society of Haematology released updates to 2 previous guidelines to help clinical laboratories with assays for coagulant diagnostic services.
Apixaban or rivaroxaban may be as safe and effective at treating upper extremity deep vein thrombosis as low molecular weight heparin and warfarin.
High or intermediate PE risk status was linked with lower rates of DVT, but asymptomatic DVT was more often found with high or intermediate PE risk.